Pharmaceuticals, Biotechnology and Life Sciences
A major research has been initiated, which will enable researchers to gain valuable insights to support advances in the development of new medicines for a wide range of serious and life threatening diseases.
Alcon, a division of Novartis, has received approval from the US Food and Drug Administration (FDA) for its AcrySof IQ ReSTOR +2.5 Multifocal Toric intraocular lens (IOL) with Activefocus optical design for patients undergoing cataract surgery who choose to address their astigmatism and presbyopia at the same time.
Verona Pharma, a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, has entered into a global strategic services agreement with QuintilesIMS, a provider of biopharmaceutical development and commercial outsourcing services.
Galapagos NV has reached a milestone in a Phase 1 study for cystic fibrosis, it is conducting with its partner AbbVie, …
Novartis’s acute heart failure (AHF) drug study did not meet its primary endpoint of reduction in cardiovascular death through Day 180 or reduced worsening heart failure through Day five when added to standard therapy
Venn Life Sciences, a Contract Research Organisation (CRO) providing drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device clients, has reported profit of €0,5 million for the 2016.
Steep Hill Labs, a cannabis science and technology company has entered a joint venture with iCAN:Israel-Cannabis to leverage Steep Hill’s science, IP, methodology, global collaboration and brand.
Novartis has reported new data suggesting, for the first time, that Cosentyx (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance.
Arix Bioscience, the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds have signed agreement to develop new therapeutics for metabolic diseases based on the discoveries from these organisations.
ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of immunotherapy products for the treatment of allergies, has appointed Gerd Zettlmeissl as its new Chairman of the Board, Béatrice De Vos having stood down to focus on new projects.